eoadjuvant pre-radical prostatectomy gene therapy (HSV-tk gene transduction followed by Ganciclovir) in patients with poor prognostic indicators.

未提供0 个研究点目标入组 12 人开始时间: 待定最近更新: 2024年2月28日

适应症

试验速览

van der Linden RRM, Haagmans BL, Mongiat-Artus P, van Doornum GJ, Kraaij R, Kadmon D, Aguilar-Cordova E, Osterhaus ADME, van der Kwast TH and Bangma CH. Virus specific immune responses after human neoadjuvant adenovirus-mediated suicide gene therapy for prostate cancer. European Urology 2005;48:153-61.

•1. Man, 35-70 years old;
•2. Histologically proven adenocarcinoma of the prostate which is clinically localized (including bone scan, not CT);

•1. Prior androgen ablation hormonal therapy (except treatment with finasteride – If discontinued > 3 months prior to inclusion);
•2. Prior surgery or other invasive treatment for BPH (i.e. TURp, hyperthermia, laser prostatectomy, etc);

发起方

未提供